MGC Pharma receives cannabis research permit for cancer testing

3d
Quick read
Summary

Business News Australia reports…….One of Australia’s top cannabis companies has today received a Cannabis Research Cultivation Permit, allowing the company to commence testing the effects of cannabis on cancer cells. MGC Pharma (ASX: MXC) will now be able to proceed with botanical research projects in collaboration with RMIT University which includes cultivating and breeding strains to test against cancer cells. Cannabis strains will be screened for anticancer activity, initially focussing on melanoma and prostate cancers. The company says the research will leverage existing MGC Pharma IP and will focus on identifying new cannabinoids and formulas to find new treatments. “The grant of a cannabis research cultivation permit is an important step forward for MXC in Australia as we continue to broaden the potential application of our phytocannabinoid derived medicinal products,” says MGX Pharma co-founder and managing director Roby Zomer. More at. https://www.businessnewsaus.com.au/articles/mgc-pharma-receives-cannabis-research-permit-for-cancer-testing.html

Article Preview

Business News Australia reports…….One of Australia’s top cannabis companies has today received a Cannabis Research Cultivation Permit, allowing the company to commence testing the effects of cannabis on cancer cells.

MGC Pharma (ASX: MXC) will now be able to proceed with botanical research projects in collaboration with RMIT University which includes cultivating and breeding strains to test against cancer cells.

Cannabis strains will be screened for anticancer activity, initially focussing on melanoma and prostate...

Read the full article @ Cannabis Law Report